Drug updated on 3/28/2024
| Dosage Form | Injection (intravenous: 200 mg) |
| Drug Class | CD19-directed cytolytic antibodies |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant (ASCT).
Summary
- Tafasitamab (Monjuvi) is indicated in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), including DLBCL arising from low grade lymphoma, who are not eligible for autologous stem cell transplant.
- Two systematic reviews/meta-analyses were reviewed to gather information about Monjuvi's efficacy and safety profile.
- In a meta-analysis involving ASCT-ineligible cohorts, tafasitamab showed promising results with the highest primary outcome being 0.47 (95% CI, 0.37 to 0.57). It was found that loncastuximab, polatuzumab plus bendamustine and rituximab along with tafasitamab did not show different efficacy than CAR T-cell therapy after adjusting for median number of previous lines of treatment.
- Another study compared the relative efficacy of TAFA + LEN versus comparator treatments such as rituximab-based combination therapies using matching-adjusted indirect comparisons (MAICs). The analysis revealed that TAFA + LEN had significantly longer duration of response [hazard ratio (HR) 0.34] when compared to POLA+BR regimen.
- Treatment with TAFA + LEN also resulted in improved overall survival rates [GO29365 comparator trial: HR 0.39], progression-free survival rates [pooled data: HR 0.39], duration of response [pooled data: HR 0.35] and complete response rate [pooled data: odds ratio 2.43].
- The findings suggest that tafasitamab combined with lenalidomide may provide better outcomes than standard treatment regimens for R/R DLBCL; however further validation from larger randomized phase-3 clinical trials is required to confirm these results.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Monjuvi (tafasitamab-cxix) Prescribing Information. | 2021 | MorphoSys US Inc., Boston, MA |
Systematic Reviews / Meta-Analyses
Clinical Practice Guidelines
| Document Title | Year | Source |
|---|---|---|
| NCCN Guidelines® Insights: B-Cell Lymphomas, Version 5.2021. | 2021 | Journal of the National Comprehensive Cancer Network |